Ask AI

Nephrology Update

 
Virtual Simulcast
 
Free CME/CE credits
 
Downloadable Slides
Nephrology Update Logo

Nephrology Update

Conference Resources

Access the slide presentations from the conference and claim credit for the sessions.

 

Dates Friday, December 4, 2026

 

Time 10:30 AM - 1:45 PM ET

 

Location Virtual

Event Schedule

December

04

2026

Nephrology Update

10:30 AM - 1:45 PM Eastern Time (ET)

Virtual

Claim Credit

To claim credit, click the link below, complete the evaluation, and you will be given access to your certificate.

Claim credit

Featured Faculty

Faculty

Andrew S. Bomback, MD, MPH

  • Associate Professor of Medicine
  • Co-Director, David Koch Jr. Glomerular Kidney Center
  • Columbia University Irving Medical Center
  • New York, New York
Faculty

Pietro A. Canetta, MD, MS, FASN

  • Associate Professor of Medicine
  • Division of Nephrology
  • Department of Medicine
  • Columbia University Irving Medical Center
  • Vagelos College of Physicians and Surgeons
  • New York, New York
Faculty

Duvuru Geetha, MD

  • Professor of Clinical Medicine
  • Johns Hopkins University School of Medicine
  • Baltimore, Maryland

Accreditation

Target Audience

This educational activity is intended for nephrology physicians, nurse practitioners and physician associates.

Learning Objectives

Upon completion of this activity, participants should be able to:

From Pathogenesis to Practice: A B-Cell–Focused Update in IgAN Management and Treatment

  • Characterize the role of B-cells and the cytokines BAFF and APRIL in the pathogenesis of IgA nephropathy
  • Differentiate the complementary and distinct functions of BAFF and APRIL, including clinical evidence supporting dual inhibition strategies in IgAN
  • Integrate updated guideline recommendations and emerging evidence to optimize treatment selection, including proteinuria reduction and remission targets, in patients with IgAN

From Dysregulation to Direction: New Horizons in C3G Management and Treatment

  • Explain the role of complement dysregulation—particularly alternative pathway overactivation—in the pathogenesis and progression of C3 glomerulopathy and related complement-mediated kidney diseases
  • Develop strategies to improve early recognition, differential diagnosis, and appropriate referral of patients with suspected C3 glomerulopathy, including interpretation of clinical features and renal biopsy findings for accurate disease classification
  • Apply evidence-based approaches to the management of complement-mediated kidney disease, including interpretation of clinical trial data on targeted therapies and integration of monitoring strategies (eGFR, proteinuria, and hematuria) to guide treatment decisions and assess disease progression

From Cascade to Clinic: Integrating Complement Inhibition Into IgAN Management

  • Analyze how dysregulation of the alternative, lectin, and terminal complement pathways contributes to immune-mediated kidney injury, proteinuria, and disease progression in IgA nephropathy
  • Evaluate the mechanistic rationale, efficacy data, and safety considerations for complement-targeted therapies under investigation or approved for the treatment of IgAN
  • Develop evidence-based treatment strategies for patients with IgAN that incorporate contemporary guidance, risk stratification, and the role of complement inhibition in reducing proteinuria and slowing CKD progression

 

JOINT ACCREDITATION INTERPROFESSIONAL CONTINUING EDUCATION

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Clinical Care Options, LLC dba Decera Clinical Education and the American Kidney Fund (AKF). Clinical Care Options, LLC dba Decera Clinical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Clinical Care Options, LLC dba Decera Clinical Education designates this live activity for a maximum of 3.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 3.0 contact hours.

Physician Associate Continuing Medical Education

Clinical Care Options, LLC dba Decera Clinical Education has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 3.0 AAPA Category 1 CME credits. PAs should only claim commensurate with the extent of their participation.

IPCE Credit Designation

This activity was planned by and for the healthcare team, and learners will receive 3.0 Interprofessional Continuing Education (IPCE) credits for learning and change.

CME Passport

The CME credits that physicians earn from this activity will be submitted to ACCME's CME Passport, a free, centralized web application where you can create a personalized account to view, track, and generate transcripts of your reported CME credit. Visit www.cmepassport.org to create your account.

Disclosure of Conflicts of Interest

Decera Clinical Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to Decera Clinical Education policy. Decera Clinical Education is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgements

From Dysregulation to Direction: New Horizons in C3G Management and Treatment
Provided by Clinical Care Options, LLC dba Decera Clinical Education in partnership with the American Kidney Fund (AKF).

Supported by Apellis Pharmaceuticals, Inc. now a subsidiary of Biogen MA Inc., and Novartis Pharmaceuticals Corporation.

From Pathogenesis to Practice: A B-Cell–Focused Update in IgAN Management and Treatment
Provided by Clinical Care Options, LLC dba Decera Clinical Education in partnership with the American Kidney Fund (AKF).

Supported by an independent educational grant from Otsuka America Pharmaceutical, Inc.

From Cascade to Clinic: Integrating Complement Inhibition Into IgAN Management
Provided by Clinical Care Options, LLC dba Decera Clinical Education in partnership with the American Kidney Fund (AKF).

This activity is supported by Alexion Pharmaceuticals

Mailing Address
Decera Clinical, LLC
12001 Sunrise Valley Drive
Suite 304
Reston, VA 20191

For customer support please email:
customersupport@deceraclinical.com